Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2007

View Archived Issues

Snapshots of clinical trials in cardiology

Orally bioavailable anthracycline penetrates the CNS in mice

Novel agents for HIV infection reported in recent Pfizer patent

Ccr2 protective in Alzheimer's disease

Genetic studies allow creation of test for clozapine-induced agranulocytosis risk

Clevudine metabolism studied in human hepatocytes

New therapeutic options for hepatitis C described in recent patent literature

Novel therapeutic agents for neurological disorders reported in recent patents

Cerus presents preclinical data on two new L. monocytogenes-based immunotherapeutics

Further analysis of CRD5 phase I/II data

ACE and NMRC begin Campylobacter challenge study

Syndax licenses selective HDAC inhibitor from Bayer Schering Pharma

Thallion updates progress of FDA Advisory Committee meeting on STEC infection

Galapagos signs new collaborations with Ono

AGI receives FDA approval for phase III study of arverapamil

Bayer and WHO sign agreement for Lampit provision for Chagas disease

MultiCell signs supply agreement with Lundbeck

Pevion and Mymetics sign virosome technology license agreement

TopoTarget to acquire Apoxis

Multikinase inhibitor from Amgen with antiangiogenic and antitumor activity

LY-2401401, a new multikinase inhibitor, presented at the AACR meeting

VEGFR inhibitor with potent antitumor activity alone and in combination

Novel series of substituted pyrroles shows promise for the treatment of breast cancer

Eisai completes Morphotek acquisition

Renvela meets primary endpoint in hyperphosphatemic patients

BNC-105, a vascular disruption agent with an improved therapeutic index

Merck seeks new indications for Gardasil for vaginal and vulvar cancers

Once-weekly formulation of risedronate sodium approved in Japan

Avastin approved in Japan for advanced or recurrent colorectal cancer

Reclast approved for Paget's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...